Top

Hepatology International

Published in:

01-04-2015 | Review Article

Recent advances in hemochromatosis: a 2015 update

A summary of proceedings of the 2014 conference held under the auspices of Hemochromatosis Australia

Authors: Dilum Ekanayake, Clinton Roddick, Lawrie W. Powell

Published in: Hepatology International | Issue 2/2015

Abstract

This review focuses on iron metabolism, the genetics of hemochromatosis, current treatment protocols and various screening methods. Even though the most common form of hereditary hemochromatosis, C282Y gene mutations in the HFE gene, has been extensively studied, novel mutations in both HFE and non-HFE genes have been implicated in this disease. These have important implications for the Asia-Pacific region. In overload, deposition of iron in various body tissues leads to toxic damage. Patients commonly present with non-specific symptoms of malaise and lethargy. Biochemical, imaging and genetic testing can be carried out to confirm diagnosis. Venesection forms the mainstay of treatment and at present cascade screening of affected families is recommended over population-level screening.

Siddique A, Kowdley KV. Review article: the iron overload syndromes. Aliment Pharmacol Ther 2012;35(8):876–893. doi:10.1111/j.1365-2036.2012.05051.x CrossRefPubMed

Zamani F, Bagheri Z, Bayat M, Fereshtehnejad SM, Basi A, Najmabadi H, et al. Iranian hereditary hemochromatosis patients: baseline characteristics, laboratory data and gene mutations. Med Sci Monit Int Med J Exp Clin Res 2012;18(10):CR622–CR629

Crownover BK, Covey CJ. Hereditary hemochromatosis. Am Fam Phys 2013;87(3):183–190

Kanwar P, Kowdley KV. Metal storage disorders: Wilson disease and hemochromatosis. Med Clin N Am 2014;98(1):87–102. doi:10.1016/j.mcna.2013.09.008 CrossRefPubMed

Guggenheim KY. Chlorosis: the rise and disappearance of a nutritional disease. J Nutr 1995;125(7):1822–1825PubMed

Trousseau A. Glycosurie, diabete sucre. Clinique medicale de l’Hotel-Dieu de Paris 1865;2:663–698

Von Recklinghausen F. Uber haemochromatose. Tageblatt Versammlung Dtsche Naturforscher Arzte Heidelberg 1889;62:324–325

Sheldon JH (1935) Haemochromatosis. Oxford University Press, Humphrey Milford, publisher to the University

Kanwar P, Kowdley KV. Diagnosis and treatment of hereditary hemochromatosis: an update. Exp Rev Gastroenterol Hepatol 2013;7(6):517–530. doi:10.1586/17474124.2013.816114 CrossRef

10.

Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G→A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002;359(9302):211–218. doi:10.1016/S0140-6736(02)07447-0 CrossRefPubMed

11.

Wood MJ, Skoien R, Powell LW. The global burden of iron overload. Hepatol Int 2009;3(3):434–444. doi:10.1007/s12072-009-9144-z CrossRefPubMedCentralPubMed

12.

European Association for the Study of the L. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol 2010;53(1):3–22. doi:10.1016/j.jhep.2010.03.001 CrossRef

13.

Fenton H. LXXIII.—Oxidation of tartaric acid in presence of iron. J Chem Soc Trans 1894;65:899–910CrossRef

14.

Lawen A, Lane DJ. Mammalian iron homeostasis in health and disease: uptake, storage, transport, and molecular mechanisms of action. Antioxid Redox Signal 2013;18(18):2473–2507. doi:10.1089/ars.2011.4271 CrossRefPubMed

15.

Haber F, Weiss J. The catalytic decomposition of hydrogen peroxide by iron salts. Proc R Soc Lond Ser A Math Phys Sci 1934;147(861):332–351CrossRef

16.

Han O. Molecular mechanism of intestinal iron absorption. Metallomics 2011;3(2):103–109. doi:10.1039/c0mt00043d CrossRefPubMed

17.

Bourdon E, Kang D-K, Ghosh MC, Drake SK, Wey J, Levine RL, et al. The role of endogenous heme synthesis and degradation domain cysteines in cellular iron-dependent degradation of IRP2. Blood Cells Mol Dis 2003;31(2):247–255CrossRefPubMed

18.

Gunshin H, Mackenzie B, Berger UV, Gunshin Y, Romero MF, Boron WF, et al. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 1997;388(6641):482–488CrossRefPubMed

19.

Greenberg GR, Wintrobe MM. A labile iron pool. J Biol Chem 1946;165(1):397–398PubMed

20.

Bartnikas TB. Known and potential roles of transferrin in iron biology. Biometals 2012;25(4):677–686CrossRefPubMedCentralPubMed

21.

Arosio P, Ingrassia R, Cavadini P. Ferritins: a family of molecules for iron storage, antioxidation and more. Biochim et Biophys Acta (BBA) Gen Subj 2009;1790(7):589–599CrossRef

22.

Ganz T. Systemic iron homeostasis. Physiol Rev 2013;93(4):1721–1741CrossRefPubMed

23.

Morgan E. Transferrin, biochemistry, physiology and clinical significance. Mol Asp Med 1981;4(1):1–123CrossRef

24.

Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim et Biophys Acta (BBA) Mol Cell Res 2012;1823(9):1434–1443CrossRef

25.

McDonald CJ, Wallace DF, Crawford DH, Subramaniam VN. Iron storage disease in Asia-Pacific populations: the importance of non-HFE mutations. J Gastroenterol Hepatol 2013;28(7):1087–1094. doi:10.1111/jgh.12222 CrossRefPubMed

26.

Zarrilli F, Elce A, Scorza M, Giordano S, Amato F, Castaldo G. An update on laboratory diagnosis of liver inherited diseases. BioMed Res Int 2013;2013:697940. doi:10.1155/2013/697940 CrossRefPubMedCentralPubMed

27.

Bassett ML, Hickman PE, Dahlstrom JE. The changing role of liver biopsy in diagnosis and management of haemochromatosis. Pathology 2011;43(5):433–439. doi:10.1097/PAT.0b013e3283490e04 CrossRefPubMed

28.

Brissot P. Hereditary hemochromatosis. Hematology 2013;18(6):370–371. doi:10.1179/1024533213Z.000000000222 CrossRefPubMed

29.

Santos PC, Cancado RD, Pereira AC, Schettert IT, Soares RA, Pagliusi RA, et al. Hereditary hemochromatosis: mutations in genes involved in iron homeostasis in Brazilian patients. Blood Cells Mol Dis 2011;46(4):302–307. doi:10.1016/j.bcmd.2011.02.008 CrossRefPubMed

30.

Radio FC, Majore S, Binni F, Valiante M, Ricerca BM, De Bernardo C, et al. TFR2-related hereditary hemochromatosis as a frequent cause of primary iron overload in patients from Central-Southern Italy. Blood Cells Mol Dis 2014;52(2):83–87CrossRefPubMed

31.

Fracanzani AL, Piperno A, Valenti L, Fraquelli M, Coletti S, Maraschi A, et al. Hemochromatosis in Italy in the last 30 years: role of genetic and acquired factors. Hepatology 2010;51(2):501–510. doi:10.1002/hep.23333 CrossRefPubMed

32.

Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology 2010;139(2):393–408. doi:10.1053/j.gastro.2010.06.013 (408 e391–e392)CrossRefPubMed

33.

Dongiovanni P, Donati B, Fares R, Lombardi R, Mancina RM, Romeo S, et al. PNPLA3 I148M polymorphism and progressive liver disease. World J Gastroenterol 2013;19(41):6969–6978. doi:10.3748/wjg.v19.i41.6969 CrossRefPubMedCentralPubMed

34.

Sood R, Bakashi R, Hegade VS, Kelly SM. Diagnosis and management of hereditary haemochromatosis. Br J Gen Pract 2013;63(611):331–332. doi:10.3399/bjgp13X668410 CrossRefPubMedCentralPubMed

35.

Sikorska K, Romanowski T, Stalke P, Izycka-Swieszewska E, Bielawski KP. Iron overload and HFE gene mutations in Polish patients with liver cirrhosis. Hepatobiliary Pancreat Dis Int 2011;10(3):270–275CrossRefPubMed

36.

Allen KJ, Gurrin LC, Constantine CC, Osborne NJ, Delatycki MB, Nicoll AJ, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008;358(3):221–230. doi:10.1056/NEJMoa073286 CrossRefPubMed

37.

Powell LW, Dixon JL, Ramm GA, Purdie DM, Lincoln DJ, Anderson GJ, et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med 2006;166(3):294–301CrossRefPubMed

38.

Adams PC, Reboussin DM, Barton JC, McLaren CE, Eckfeldt JH, McLaren GD, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005;352(17):1769–1778. doi:10.1056/NEJMoa041534 CrossRefPubMed

39.

Castiella A, Zapata E, Otazua P, Zubiaurre L, Fernandez J. Non-HFE–related hemochromatosis: the role of genetic factors. Hepatology 2010;51(4):1473–1474CrossRefPubMed

40.

Camaschella C, Poggiali E. Rare types of genetic hemochromatosis. Acta Haematol 2009;122(2–3):140–145. doi:10.1159/000243798 CrossRefPubMed

41.

Bardou-Jacquet E, Cunat S, Beaumont-Epinette MP, Kannengiesser C, Causse X, Sauvion S, et al. Variable age of onset and clinical severity in transferrin receptor 2 related haemochromatosis: novel observations. Br J Haematol 2013;162(2):278–281CrossRefPubMed

42.

Cadet E, Capron D, Perez AS, Crepin SN, Arlot S, Ducroix JP, et al. A targeted approach significantly increases the identification rate of patients with undiagnosed haemochromatosis. J Intern Med 2003;253(2):217–224CrossRefPubMed

43.

Bacon BR, Sadiq SA. Hereditary hemochromatosis: presentation and diagnosis in the 1990s. Am J Gastroenterol 1997;92(5):784–789PubMed

44.

Timms AE, Sathananthan R, Bradbury L, Athanasou NA, Wordsworth BP, Brown MA. Genetic testing for haemochromatosis in patients with chondrocalcinosis. Ann Rheum Dis 2002;61(8):745–747CrossRefPubMedCentralPubMed

45.

Swinkels DW, Aalbers N, Elving LD, Bleijenberg G, Swanink CM, van der Meer JW. Primary haemochromatosis: a missed cause of chronic fatigue syndrome? Neth J Med 2002;60(11):429–433PubMed

46.

Falize L, Guillygomarc’h A, Perrin M, Laine F, Guyader D, Brissot P, et al. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology 2006;44(2):472–477. doi:10.1002/hep.21260 CrossRefPubMed

47.

Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS, American Association for the Study of Liver D. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the study of liver diseases. Hepatology 2011;54(1):328–343. doi:10.1002/hep.24330 CrossRefPubMedCentralPubMed

48.

Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999;341(10):718–724. doi:10.1056/NEJM199909023411002 CrossRefPubMed

49.

Adams PC, Agnew S. Alcoholism in hereditary hemochromatosis revisited: prevalence and clinical consequences among homozygous siblings. Hepatology 1996;23(4):724–727. doi:10.1002/hep.510230411 CrossRefPubMed

50.

Hutchinson C, Geissler CA, Powell JJ, Bomford A. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut 2007;56(9):1291–1295. doi:10.1136/gut.2006.108613 CrossRefPubMedCentralPubMed

51.

Morrison ED, Brandhagen DJ, Phatak PD, Barton JC, Krawitt EL, El-Serag HB, et al. Serum ferritin level predicts advanced hepatic fibrosis among US patients with phenotypic hemochromatosis. Ann Intern Med 2003;138(8):627–633CrossRefPubMed

52.

Jehn M, Clark JM, Guallar E. Serum ferritin and risk of the metabolic syndrome in US adults. Diabetes Care 2004;27(10):2422–2428CrossRefPubMed

53.

ST Pierre TG, Clark PR, Chua-Anusorn W. Measurement and mapping of liver iron concentrations using magnetic resonance imaging. Ann N Y Acad Sci 2005;1054(1):379–385CrossRefPubMed

54.

Harrison SA, Bacon BR. Hereditary hemochromatosis: update for 2003. J Hepatol 2003;38:14–23

55.

Eijkelkamp EJ, Yapp TR, Powell LW. HFE associated hereditary hemochromatosis. Can J Gastroenterol 2000;14:121–125

Title: Recent advances in hemochromatosis: a 2015 update
A summary of proceedings of the 2014 conference held under the auspices of Hemochromatosis Australia
Authors: Dilum Ekanayake
Clinton Roddick
Lawrie W. Powell
Publication date: 01-04-2015
Publisher: Springer India
Published in: Hepatology International / Issue 2/2015
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI: https://doi.org/10.1007/s12072-015-9608-2

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Recent advances in hemochromatosis: a 2015 update

A summary of proceedings of the 2014 conference held under the auspices of Hemochromatosis Australia

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2015

Influence of IFNL3.rs12979860 and IFNL4.ss469415590 polymorphism on clearance of hepatitis C virus infection among Egyptians

Sofosbuvir for treatment of chronic hepatitis C

Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years

Long-term use of methotrexate does not result in hepatitis B reactivation in rheumatologic patients

Association between retinal artery lesions and nonalcoholic fatty liver disease

Autoimmune liver disease in Asian children

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page